Newsroom

GHENT, Bélgica & TÓQUIO--(BUSINESS WIRE)--A H.U. Group Holdings Inc. e sua subsidiária integral Fujirebio anunciaram hoje que a Fujirebio Europe N.V. obteve o certificado CE para o ensaio Lumipulse G pTau 217 Plasma, nos termos do Regulamento (UE) 2017/746 relativo aos dispositivos médicos para diagnóstico in vitro (IVDR). Este teste CLEIA (imunoensaio enzimático quimioluminescente) permite a medição quantitativa da proteína Tau fosforilada na treonina 217 (pTau 217) no plasma humano (2 EDTA)....

GENT, Belgien & TOKIO--(BUSINESS WIRE)--Die H.U. Group Holdings Inc. und ihre hundertprozentige Tochtergesellschaft Fujirebio gaben heute bekannt, dass Fujirebio Europe N.V. ein CE-Zertifikat für den Lumipulse G pTau 217 Plasma-Assay gemäß der Verordnung (EU) 2017/746 über In-vitro -Diagnostika (IVDR) erhalten hat. Dieser CLEIA-Test (Chemilumineszenz-Enzymimmunoassay) ermöglicht die quantitative Bestimmung von an Threonin 217 phosphoryliertem Tau (pTau 217) in humanem Plasma (K2 EDTA). „Mit den...

GAND, Belgique et TOKYO, Japon--(BUSINESS WIRE)--H.U. Group Holdings Inc. et sa filiale à 100 %, Fujirebio, ont annoncé aujourd’hui que Fujirebio Europe N.V. a obtenu le marquage CE pour le test Lumipulse® G pTau 217 Plasma, conformément au règlement (UE) 2017/746 relatif aux dispositifs médicaux de diagnostic in vitro (IVDR). Ce test CLEIA (dosage immunoenzymatique par chimiluminescence) permet la mesure quantitative de la protéine tau phosphorylée en thréonine 217 (pTau 217) dans le plasma hu...

GENT (Bélgica) y TOKIO--(BUSINESS WIRE)--H.U. Group Holdings Inc. y su filial de propiedad exclusiva Fujirebio anunciaron hoy que Fujirebio Europe N.V. ha obtenido el certificado CE para el ensayo Lumipulse G pTau 217 Plasma, de conformidad con el Reglamento (UE) 2017/746 sobre productos sanitarios para diagnóstico in vitro (IVDR). Este ensayo inmunoenzimático por quimioluminiscencia (CLEIA, por sus siglas en inglés) permite la medición cuantitativa de la proteína Tau fosforilada en treonina 21...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, today clarifies the objectives and criteria selected for the analysis of a predictive biomarker associated with NFL-101, its drug candidate for smoking cessation. The objectives associated with the validation of a predictive efficacy biomarker are to strengthen the probability of...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News : NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), société biopharmaceutique développant des médicaments botaniques innovants pour le traitement des addictions, précise aujourd’hui les enjeux et les critères retenus pour l’analyse d’un biomarqueur prédictif associé à NFL-101, candidat-médicament dans le sevrage tabagique. Les enjeux liés à la validation d’un biomarqueur prédictif d’efficacité sont de renforcer la probabilité d...

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 04/05/2026 FR0014000MR3 45 000 57.9715 XPAR EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 04/05/2026 FR0014000MR3 15 000 57.9946 CEUX EUROFINS SCIENTIFC 529900JEHFM47D...

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against monday.com Ltd. (“monday.com” or the “Company”) (NASDAQ: MNDY) and reminds investors of the May 11, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm ha...

NEW YORK--(BUSINESS WIRE)--KBRA assigns preliminary ratings to 74 classes of mortgage pass-through certificates from Sequoia Mortgage Trust 2026-INV3 (SEMT 2026-INV3). The transaction consists of 1,275 mortgages with an aggregate principal balance of $507.1 million as of the May 1, 2026 cut-off date. The collateral is characterized by a weighted average (WA) original credit score of 768 and moderate borrower equity, with a WA original LTV and WA original CLTV of 70.9%. KBRA’s rating approach in...

NEW HYDE PARK, N.Y.--(BUSINESS WIRE)--Northwell Health, New York’s largest health system, and Matthew Schaefer, the No. 1 overall pick in the 2025 NHL draft and one of New York hockey’s most promising young stars, announced a new relationship today to help cancer patients and their families find moments of joy while going through the most difficult journeys of their lives. For Schaefer – nominated at just 18 years old for the prestigious Calder Memorial Trophy, awarded to the National Hockey Le...